Compounding Oversight May Hinge On How FDA Treats Office Stock
Executive Summary
Pew asks FDA to look at large-scale compounders of office stocks and help encourage them to register, but IACP argues regulation of the office stock should remain with the states.
You may also be interested in...
FDA's Budget Flat In House Bill, But Path For 'Cures' Funding Cleared
US agency's budget authority would remain at current level under FY 2018 appropriations bill reported out by a House subcommittee; measure includes language enabling FDA's Oncology Center of Excellence to receive 21st Century Cures funding transferred from National institutes of Health.
FDA Compounder Inspections May Help Set New Enforcement Standard
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
Neonatal Drug Development Could Benefit From Rare Disease Experience
Early parent involvement in drug development and clinical trial design could improve recruitment and outcomes, stakeholders argue.